PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
3.49%
Revenue growth under 50% of META's 12.29%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
4.69%
Gross profit growth under 50% of META's 12.33%. Michael Burry would be concerned about a severe competitive disadvantage.
2.05%
EBIT growth below 50% of META's 10.27%. Michael Burry would suspect deeper competitive or cost structure issues.
2.05%
Operating income growth under 50% of META's 16.44%. Michael Burry would be concerned about deeper cost or sales issues.
-4.57%
Negative net income growth while META stands at 10.17%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-0.70%
Negative EPS growth while META is at 10.47%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-2.00%
Negative diluted EPS growth while META is at 11.04%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.22%
Slight or no buybacks while META is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
0.20%
Slight or no buyback while META is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
-0.75%
Negative OCF growth while META is at 6.39%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
13.95%
Positive FCF growth while META is negative. John Neff would see a strong competitive edge in net cash generation.
4673.69%
10Y revenue/share CAGR above 1.5x META's 1223.16%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
1789.24%
5Y revenue/share CAGR above 1.5x META's 190.49%. David Dodd would look for consistent product or market expansions fueling outperformance.
234.44%
3Y revenue/share CAGR above 1.5x META's 77.04%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
No Data
No Data available this quarter, please select a different quarter.
2922.92%
5Y OCF/share CAGR above 1.5x META's 653.02%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
143.93%
3Y OCF/share CAGR 1.25-1.5x META's 125.05%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
5055.68%
Net income/share CAGR above 1.5x META's 2770.56% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
4147.72%
5Y net income/share CAGR above 1.5x META's 304.58%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
213.91%
3Y net income/share CAGR similar to META's 194.47%. Walter Schloss would attribute it to shared growth factors or demand patterns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
465.40%
3Y equity/share CAGR above 1.5x META's 66.56%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.16%
AR growth is negative/stable vs. META's 14.10%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
31.62%
Inventory growth of 31.62% while META is zero. Bruce Berkowitz wonders if we anticipate a new wave of demand or risk being stuck with extra product.
5.70%
Asset growth 1.25-1.5x META's 5.19%. Bruce Berkowitz sees if the firm's investments effectively outpace the competitor in future returns.
6.24%
Similar to META's 5.80%. Walter Schloss finds parallel capital usage or profit distribution strategies.
No Data
No Data available this quarter, please select a different quarter.
1.36%
R&D dropping or stable vs. META's 6.52%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
12.06%
SG&A growth well above META's 12.01%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.